Relay Therapeutics Statistics
Want to see RLAY full AI Analyst Report?
Relay Therapeutics (RLAY) Stock Statistics & Valuation Metrics
Total Valuation
Relay Therapeutics has a market cap or net worth of $4.11B. The enterprise value is $3.13B.
- Market Cap
- $4.11B
- Enterprise Value
- $3.13B
Share Statistics
Relay Therapeutics has 220,959,470 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 220,959,470
- Owned by Insiders
- 11.42%
- Owned by Institutions
- 39.69%
Financial Efficiency
Relay Therapeutics’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -50.50%.
- Return on Equity (ROE)
- -0.49
- Return on Assets (ROA)
- -0.44
- Return on Invested Capital (ROIC)
- -50.50%
- Return on Capital Employed (ROCE)
- -0.51
- Revenue Per Employee
- 76.01K
- Profits Per Employee
- -1.37M
- Employee Count
- 202
- Asset Turnover
- 0.02
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Relay Therapeutics is -13.50. Relay Therapeutics’s PEG ratio is -0.90.
- PE Ratio
- -13.50
- PS Ratio
- 431.72
- PB Ratio
- 5.46
- Price to FCF
- -20.88
- Price to Operating Cash Flow
- -20.88
- PEG Ratio
- -0.90
Income Statement
In the last 12 months, Relay Therapeutics had revenue of 15.36M and earned -276.48M in profits. Earnings per share was -1.61.
- Revenue
- 15.36M
- Gross Profit
- 11.80M
- Operating Income
- -302.74M
- Pretax Income
- -276.48M
- Net Income
- -276.48M
- EBITDA
- -272.92M
- Earnings Per Share (EPS)
- -1.61
Cash Flow
In the last 12 months, operating cash flow was -214.02M and capital expenditures -1,000, giving a free cash flow of -214.02M billion.
- Operating Cash Flow
- -214.02M
- Free Cash Flow
- -214.02M
- Free Cash Flow per Share
- -0.98
Dividends & Yields
Relay Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -4.79%
- Earnings Yield
- -6.57%
Stock Price Statistics
- Beta
- 1.88
- 52-Week Price Change
- 184.84%
- 50-Day Moving Average
- 18.32
- 200-Day Moving Average
- 15.39
- Relative Strength Index (RSI)
- 52.71
- Average Volume (3m)
- 2.88M
Important Dates
Relay Therapeutics upcoming earnings date is Feb 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Feb 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Relay Therapeutics as a current ratio of 22.61, with Debt / Equity ratio of 5.72%
- Current Ratio
- 22.61
- Quick Ratio
- 22.61
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.19
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Relay Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Relay Therapeutics EV to EBITDA ratio is -14.98, with an EV/FCF ratio of -20.42.
- EV to Sales
- 422.33
- EV to EBITDA
- -14.98
- EV to Free Cash Flow
- -20.42
- EV to Operating Cash Flow
- -20.42
Balance Sheet
Relay Therapeutics has $848.64M in cash and marketable securities with $27.03M in debt, giving a net cash position of $821.61M billion.
- Cash & Marketable Securities
- $848.64M
- Total Debt
- $27.03M
- Net Cash
- $821.61M
- Net Cash Per Share
- $3.72
- Tangible Book Value Per Share
- $3.72
Margins
Gross margin is 89.34%, with operating margin of -3094.59%, and net profit margin of -2837.03%.
- Gross Margin
- 89.34%
- Operating Margin
- -3094.59%
- Pretax Margin
- -2837.03%
- Net Profit Margin
- -2837.03%
- EBITDA Margin
- -2820.19%
- EBIT Margin
- -2837.03%
Analyst Forecast
The average price target for Relay Therapeutics is $29.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $29.33
- Price Target Upside
- 57.71% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 7
- Revenue Growth Forecast
- 23.86%
- EPS Growth Forecast
- 13.76%
Scores
- Smart Score
- 8
- AI Score
- 51
